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Results Reduction in BAA was significantly higher in 
group-A compared to group-B already by 6 m. Despite the 
transiently significant decrease in height velocity in group-
A, gain in PAH SD was almost double by 12 and 18 m 
vs group-B and reached the maximum of +1.21 ± 0.45 
(7.51 cm) vs +0.31 ± 0.37 (1.92 cm, p = 0.001) in group-
B at 24 m. Group-A had no clinical or biochemical hyper-
androgenism, unchanged normal bone density, and lumbar 
spine X-rays.
Conclusion The co-administration of anastrozole with 
leuprorelin safely improves PAH in girls with compro-
mised growth.
Keywords Aromatase inhibitors · Anastrozole · LHRH 
analogues · Early puberty · Girls
Introduction
Third generation aromatase inhibitors (AI), mainly 
anastrozole and letrozole, have been used to increase 
predicted adult height (PAH) [1, 2] in boys with consti-
tutional delay of growth and puberty (CDGP) [3], idi-
opathic short stature (ISS) [4–6], and growth hormone 
deficiency (GHD) [6, 7], as well as in testotoxicosis [8], 
and gynecomastia [9–11], but in girls only in the con-
text of McCune-Albright syndrome [12–14] apart from 
one case report of a girl with a recurrent autonomous 
ovarian cyst [15]. The reluctance of using of aromatase 
inhibitors in girls stems from the theoretical concern of 
secondary hyperandrogenism and ovarian cyst formation 
[16, 17].
To relieve and overcome these concerns, we combined 
anastrozole with an LHRH analogue in girls with preco-
cious puberty (PP) or early puberty (EP) and compromised 
Abstract 
Purpose Aromatase inhibitors have been used to increase 
predicted adult height (PAH) in boys but in girls only in 
McCune-Albright syndrome. We investigated whether 
anastrozole combined with leuprorelin for up to 2 years 
is safe and effective in improving PAH in girls with early 
puberty and compromised growth, compared to leuprorelin 
alone.
Methods The “GAIL” study: girls treated with 
an aromatase inhibitor and an LHRH analogue, 
ISRCTN11469487, was a 7-year prospective phase IIa 
study with parallel design, performed at Athens Medical 
Center (C-A), and Attikon University Hospital, Athens, 
Greece (C-B). Forty girls, consecutively referred for early 
puberty (onset 7.5–9 years) with a PAH <−2 or >1.5 SD 
lower than their target height (TH), were included. Twenty 
started on leuprorelin sc/im 0.3 mg/kg/month plus anas-
trozole 1 mg/d p.o. (group-A, C-A) and 20 on leuprorelin 
(group-B, C-B) for 2 years or until the age of 10 years. 
Groups did not differ in age, height, BMI, bone age 
advancement (BAA), and distance of PAH from TH. Fol-
low-up was at 6, 12, 18, and 24 m.
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growth potential [median PAH 145.4 cm with a median 
target height (TH) of 161 cm] in a small pilot clinical trial 
[18]. In that study, 5 girls (aged 6.3–11.5 years) received 
leuprorelin 11.25 mg/12 weeks s.c./i.m. and anastrozole 
1 mg/day p.o. for 1–3 years. There was a net significant 
increase in PAH of +4.5 cm already by the end of the 1st 
year. None developed ovarian cysts or other signs of hyper-
androgenism or any other systematic side effects, while 
bone mineral density (BMD) evaluated yearly remained 
unchanged [DXA scans showed z scores (corrected for 
height) within normal range for BA without significant 
inter-patient changes].
It has been already shown that in EP and in borderline 
PP, inhibition of puberty alone is not as effective as initially 
expected in improving PAH, with most studies showing a 
gain of 2 cm or less after a 2-year treatment with an LHRH 
analogue (LHRHa) [19]. On the other hand, atypical forms 
of early puberty not driven by LH, such as those occurring 
in cases of premature or exaggerated adrenarche, do not 
seem to respond to LHRH analogues at least in terms of 
bone maturation and gain in adult height [20].
These facts led us to plan and implement a phase IIa 
prospective parallel group study, the “GAIL” study: girls 
treated with an Aromatase Inhibitor and Leuprorelin, to 
investigate whether the combination of anastrozole and leu-
prorelin could significantly improve PAH in girls with EP 
and a compromised growth potential, compared to inhibi-
tion of puberty alone.
Materials and methods
The “GAIL” study ISRCTN11469487 was a 7-year pro-
spective study that was performed between 2008 and 2014 
in the pediatric endocrine units of the Athens Medical 
Center (Center-A) and of the Attikon University Hospital 
(Center-B), Athens, Greece. Inclusion started on March 
2008 and ended on December 2013. The institutional 
review boards of both institutions approved the study. Writ-
ten informed consent was obtained from at least one parent 
in group-B and from both parents in group-A, as this was 
an off-label treatment.
Inclusion criteria
Forty girls with idiopathic early puberty, i.e. breast develop-
ment between 7.5 and 9 years [21], with a PAH—calculated 
according to the Bayley–Pinneau method using the average 
girls’ prediction tables [22, 23]—lower than −2 or −1.5 
SD lower than their TH (mid parental height −6.5 cm), 
previously naïve to any hormonal therapy, consecutively 
referred to the above centers, were enrolled for a maximum 
period of 2 years, or until the age of 10 years [24]. Girls 
with organic PP, syndromic, systemic or hereditary condi-
tions that either impair growth or associate with PP, as well 
as bone diseases related to short stature (i.e. hypochondro-
plasia) ,were excluded from the study. Diagnosis of PP was 
based upon clinical examination and laboratory evaluation 
including a positive LHRH test [peak LH ≥5 IU/L at 30′ or 
60′ after i.v. administration of gonadorelin 100 μg/m2–max 
100 μg (Relefact LHRH®, Ferring SAS)] associated with 
elevated basal E2 ≥ 15 pg/mL and pubertal configuration 
of the internal genitalia on the pelvic ultrasound: maximum 
uterine length ≥35 mm, pear shaped (uterine/cervix width 
>1), ovaries ≥3 mL with the presence of stimulated folli-
cles ≥6 mm in diameter). BA was advanced more than the 
expected difference in years between their height percen-
tile and their TH percentile, as these girls did not follow 
the well-recognized pattern of constitutional advancement 
of growth and puberty (CAG) [25]. Girls in Center-B were 
offered inhibition of puberty with leuprorelin and those 
in Center-A inhibition of puberty with leuprorelin com-
bined to the AI anastrozole. Patient characteristics forming 
group-A and group-B are shown in detail in Table 1.
Study design
A complete physical examination with accurate height 
measurements (and of both parents), pubertal Tanner stag-
ing, a bone age X-ray, a pelvic ultrasound by a pediatric 
radiologist, as well as the required biochemical testing (at 
0800 h and after an overnight fast) were obtained at inclu-
sion. These studies were repeated on the day of the sched-
uled injection with leuprorelin every 6 months during 
follow-up.
Each girl enrolled was consecutively followed by the 
same experienced Pediatric Endocrinologist: D.T.P in 
Table 1  Patient characteristics (mean ± SD)
LHRHa LHRH analogue, AI aromatase inhibitor, BA bone age, BMI body mass index, TH target height, PAH predicted adult height
Group Age (years) Height (SDS) BMI (SDS) TH (SDS) TH-PAH (SDS) Bone age advancement 
(years)
A: LHRHa + AI (n = 20) 8.91 (±0.98) −0.19 (±1.36) 1.15 (±0.89) −0.27 (±0.80) −2.17 (±1.00) 1.88 (±1.11)
B: LHRHa (n = 20) 8.46 (±0.65) 0.53 (±0.83) 1.13 (±1.08) 0.15 (±0.73) −1.81 (±0.58) 1.95 (±0.67)
p 0.058 0.06 0.47 0.055 0.09 0.40
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Center-A and A.P. in Center-B. Bone ages were evaluated 
blindly according to the Atlas of Greulich and Pyle by an 
experienced Pediatric Radiologist G.P., who did not work 
in either institution. G.P. did not have access to the previous 
readings or the growth chart in the patients’ medical files, 
nor the regimen the patients were receiving apart from their 
birth dates.
All measurements, BA readings, and PAH calculations 
were entered, calculated by and analyzed in growth ana-
lyser 3.5 (Copyright© 2001–2006, Dutch growth founda-
tion), using the country default growth curves (for height: 
Papadimitriou A. 1995, for BMI: The Netherlands 1997, 
for height velocity: British 1996).
At inclusion a blood count, concentrations of lipids, 
glucose, calcium, phosphate, alkaline phosphatase, liver 
enzymes, total vitamin D* and parathyroid hormone* as 
well as LH*, FSH*, testosterone, and estradiol (*ECLIA, 
Elecsys immunoassay analyzer, Roche) were performed. 
Sex steroids and 17OH-progesterone levels were measured 
by liquid chromatography/tandem mass spectrometry (LC/
MS–MS). 17OH-progesterone was <1.5 ng/mL in all cases 
excluding the possibility of late onset congenital adrenal 
hyperplasia (CAH). Those with a vitamin D deficiency 
(i.e. total vit D <20 ng/mL) received proper replacement 
therapy (i.e. 2000 IU cholecalciferol p.o. daily for 2 months 
and as needed thereafter) [26].
Dual-energy X-ray absorptiometry (DXA) as well as 
anterior-posterior/lateral X-ray of the lumbar spine was 
performed at inclusion and yearly thereafter in group-
A patients only. BMD was measured at the lumbar spine 
(L1–L4) by DXA with a Hologic QDR-1000 upgraded unit 
(Hologic Inc., Bedford, MA, USA) and was expressed as 
z scores (calculated according to the BA and corrected for 
height). As reference data for BMD were used the ones 
provided by the manufacturer of the Hologic densitometer, 
for Caucasians. The lumbar spine X-rays were evaluated by 
a pediatric radiologist and were re-evaluated each time in 
comparison with the previous ones in each patient.
Treatment for EP was with leuprorelin acetate 0.3 mg/
kg/month with the 3-month 11.25 mg depot s.c./i.m. injec-
tion (Elityran®) [27]. All patients had an LHRH stimulation 
test (0′–30′–60′) performed on the day of and prior to the 
second scheduled leuprorelin injection with measurement 
of E2 levels and evaluation of the internal genitalia matura-
tion in the pelvic ultrasound.
Treatment with anastrozole tablets started simulta-
neously at a dose of 1 mg once daily p.o. (Arimidex®). 
Patients were followed at 6-month intervals. Parents were 
advised to report any sign of hyperandrogenism (acne, hir-
sutism, hair loss) as well as incidents of peculiar behavior. 
Medication was electronically prescribed and covered by 
the patient’s social security at 75 %, which assured compli-
ance with the treatment.
Statistics
Changes in PAH and in the rest of the parameters presented 
in the results section between baseline and at 6, 12, 18, 
and 24 months of treatment was compared using only data 
from the girls that completed each visit. Analysis between 
groups was performed with the use of the two-sample two-
sided t test. Significance was set as a p value <0.05.
Fig. 1  A STARD (STAndards 
for the Reporting of Diagnostic 
accuracy studies) flow diagram 
showing the disposition of 
subjects participating in the 
current study
Girls with Early Puberty
assessed for eligibility:
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Results
The flow chart of the study subjects is shown in 
Fig. 1. Subjects in group-A (n = 20 from Center-A) 
and group-B (n = 20 from Center-B) did not differ 
in age, height, BMI, BAA, and distance of PAH from 
TH (Table 1). Evolution of those parameters including 
also height velocity (HV) is presented in Table 2. Gain 
in PAH and BAA is presented in Fig. 2. All girls had 
adequate pubertal inhibition: peak LH <2 IU/L—during 
an LHRH stimulation test (0′–30′–60′) performed on 
the day of and prior to the second scheduled leuprore-
lin injection, E2 levels <15 pg/mL and regression of 
breast development as well as of the internal genitalia 
maturation in the pelvic ultrasound (maximum uterine 
length <35 mm with the ovaries regressing to <3 mL). 
The girls on LHRHa only did not present a significant 
reduction in BA advancement (BAA): +1.82 ± 0.45 
at 24 months from +1.95 ± 0.67 years at inclusion 
(p = 0.07). Despite the initial significant drop in HV 
of group-A at 6 months, which however, did not per-
sist thereafter, there was a significant gain in PAH in 
group-A at 12 months: +3.72 cm and even more at 18: 
+5.77 cm and at 24 months: +7.51 cm compared to 
group-B: +1.98 cm at 12 months (p = 0.01), +3.16 cm 
at 18 months (p = 0.02) and +1.92 cm at 24 months 
(p = 0.001) (Table 2). This was achieved because of the 
significantly higher reduction in BAA of the group-A 
related to that of the group-B, statistically significant 
already at 6 months (p < 0.001) with a maximum at 
24 months (Table 2).
Girls in group-A did not develop clinical or biochemi-
cal hyperandrogenism or any other side effect. Testoster-
one levels rose slightly but not significantly and did not 
exceed 0.5 ng/ml during treatment in any of the girls in 
group-A: 0.23 ± 0.14 at inclusion, 0.22 ± 0.16 (p = 0.92) 
at 6 months, 0.39 ± 0.34 (p = 0.14) at 12 months, 
0.32 ± 0.21 (p = 0.1) at 18 months, and 0.38 ± 0.35 
(p = 0.58) at 24 months. None presented ovarian cysts or 
ovarian stromal hyperplasia and there were no reports of 
peculiar behavior in any of them. Hematocrit, biochemical, 
and lipid profiles did not change during treatment. DXA 
scans showed normal BMD z scores for BA: −0.04 ± 1.1 
at inclusion, −0.17 ± 1.07 at 12 months (p = 0.39), and 
+0.35 ± 1.14 at 24 months (p = 0.24) without significant 
inter-patient change during treatment. X-rays of the lum-
bar spine did not show any abnormalities before, during,or 
at the end of treatment. Basal gonadotropins and estradiol 
levels were appropriately suppressed (LH <0.2 IU/L, FSH 
<2 IU/L and E2 <15 pg/mL) and did not differ between 
groups at any time point.
Discussion
With this study we investigated prospectively whether the 
combination of an AI to an LHRHa could significantly 
improve PAH in girls with EP and compromised growth, 
compared to inhibition of puberty alone. Although we 
acknowledge as a major limitation that this was not a ran-
domized double-blind placebo controlled trial, the study 
design simulated randomization as much as possible and 
moreover there was a control group. A parallel study design 
was chosen, matching each arm of the study with each of 
the two participating centers as it was judged extremely 
difficult to obtain parental consent for a potentially off-
label treatment with the parents being blind to it. In order 
to avoid possible biases, every girl who was consecutively 
referred for pubertal evaluation in each center was assessed 
for eligibility and only those that met the inclusion crite-
ria and had parental written informed consent entered the 
study. To increase accuracy, all the parameters presented 
in the results section were compared between baseline and 
at 6, 12, 18, and 24 months using only data from those 
girls that completed each visit and not with the whole of 
each group at inclusion. We acknowledge the progressive 
decrease in sample size throughout the study, but at least 
50 % of the girls completed 2 years of treatment. This was 
due to the fact that many reached the age of 10, while at the 
moment of data analysis still some of the girls had ongoing 
visits. The results, however, were straightforward showing 
a net gain of +7.51 cm in PAH at 24 months in the girls 
treated with the combination therapy vs +1.92 cm with 
inhibition of puberty alone.
The gain in PAH in the anastrozole group confirmed 
our preliminary results from the pilot study [18] and was 
in accordance with the abstract of A.L. Turpin et al. who 
presented a retrospective study, in which 7 from 19 girls 
treated with letrozole were concomitantly treated with 
LHRH analogues [28]. It was also comparable to those 
of Mauras et al. [7], in adolescent males with GHD and 
daily co-treatment with anastrozole, that resulted in a 
net increase in PAH of 6.8 cm at 36 months vs 1 cm in 
the placebo group. Similar results published recently by 
Neely EK et al. showed a gain in PAH of 4.2 ± 3.5 cm 
in peripubertal boys with daily administration of anastro-
zole vs 1.4 ± 4.4 cm with letrozole after 1 year [5]. While 
AI have nowadays become an established—even if still 
an off-label treatment in boys—and this is proven by the 
fact that recent studies compare directly letrozole to anas-
trozole in short boys without even a control group [5], to 
our knowledge this is the first prospective study ever con-
ducted in girls, outside the context of McCune Albright 
syndrome.





























































































































































































































































































































































































































































































































































































































































































































































































































































































444 J Endocrinol Invest (2016) 39:439–446
1 3
The theoretical concern of hyperandrogenism [16, 17] 
was overcome with the simultaneous use of LHRHa, keep-
ing the gonadotropins and estradiol adequately suppressed. 
Thus, the small—even if not statistically significant—rise 
in testosterone levels could not result in any direct andro-
genic action on LH regulation [29]. Moreover, recent data 
on the use of AI as a treatment of infertility in the poly-
cystic ovary syndrome are reasonably reassuring on safety 
concerns on possible direct deleterious effects on the ova-
ries [30, 31], whereas measurement of the anti-mullerian 
hormone levels may indeed be of value but only in the case 
of monotherapy with AI in girls [32].
The fact that gonadotropins and estradiol levels did not 
differ between the two groups implies that peripheral aro-
matization of mainly adrenal but also of ovarian androgens 
may be the main mechanism of BAA in these girls [1], 
with extragonadal estrogen biosynthesis, particularly in the 
bone, deploying a “paracrine” or “intracrine” action [33]. 
Moreover, the fact that estradiol levels, even if suppressed 
to below the detection limit in girls treated with leuprorelin 
for PP, do not correlate with the rate of skeletal maturation 
or linear growth [34] implies that AI may prove efficacious 
in delaying bone maturation even in prepubertal children 
with a compromised growth potential.
There was initially a significantly higher drop in HV in 
the anastrozole group that did initially raise concerns in 
some parents but without any implications on compliance. 
Although this finding did not persist, we speculate that it 
probably has to do with lower circulating levels of E2 in 
group-A, even if still in the prepubertal range. This implies 
that we may use the least possible dose of an LHRHa if aro-
matase inhibitors are added. This approach would not only 
simplify follow-up but may prove cost-effective as well, as 
intensifying treatment with LHRHa is particularly costly.
Apart from the well-recognized and described pattern of 
Constitutional Advancement of Growth [35], that obviously 
does not require treatment, in girls with advanced puberty, 
borderline PP, precocious slowly progressive and early rapidly 
progressive puberty, inhibition of puberty alone does not result 
in significant improvement in terms of height at least after age 
8 [19, 36, 37], and moreover its benefits in patients with atypi-
cal forms of early puberty not driven by LH (i.e. exaggerated 
adrenarche followed by early puberty) are not well defined 
[20]. The co-administration of AI appears to provide the poten-
tial for meaningful height gain in girls with borderline preco-
cious or early—rapidly progressive or not—puberty, apart from 
the individualized possible psychological relief that pubertal 
inhibition might offer. One might also consider starting an 
LHRHa alone and add an AI in those cases that BAA does not 
respond to treatment [18]. It is noteworthy that the maximum 
gain in the girls treated with leuprorelin only in our study was 
observed at 18 months (+3.16 cm) and that further continua-
tion of pubertal inhibition may indeed result in loss rather than 
in further gain as far as PAH is concerned, which is in accord-
ance with Carel et al. [24]. This was not the case in group-A, 
who continued to ameliorate their PAH at 24 months. In any 
case the decision on the duration of the intervention must be 
individualized taking into account the patient’s age, HV, and 
response of BAA to the combined treatment. Aiming at the 
lowest normal female adult height or at an SDS lower than 
Fig. 2  Reduction in bone age 
advancement (BAA, years: left 
side) and gain in predicted adult 
height PAH (SDS: right side) 
in group-A (LHRHa + AI) and 















6 m                 12 m                18 m               24 m 6 m                 12 m                18 m               24 m 
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the patient’s TH may be an acceptable target with a reasonable 
rationale from the doctor as well as the patient and their family.
The fact that bone mineral density, hematologic, bio-
chemical, and lipid profiles did not show any changes dur-
ing treatment suggests that the co-administration of AI with 
an LHRHa in girls is safe. Moreover, having excluded from 
the study children with possible bone diseases or abnor-
malities, the thorough examination of lumbar spine X-rays 
before and during treatment showed no alterations. This 
relieves the concern that was raised by Hero et al. [38], 
who reported the detection of asymptomatic or mildly 
symptomatic vertebral wedge deformities in boys with ISS 
previously treated with letrozole vs placebo, although there 
was no statistical difference between the occurrence rate in 
the two groups and baseline studies were not performed. In 
addition, very recently it was reported that more than 20 % 
of children with ISS present skeletal dysplasia [39].
Further follow-up is needed to examine whether this 
gain in PAH is translated indeed in higher near-adult height 
in these girls after discontinuation of treatment.
In conclusion, inhibition of puberty with leuprorelin and 
co-administration of the third generation aromatase inhibitor 
anastrozole for up to 2 years is a safe and effective strategy 
in ameliorating poor PAH in girls with early puberty and a 
compromised growth potential. Further studies are needed 
to confirm these results, to evaluate the effect of AI on adult 
height, as well as long-term safety of the use of AI in girls.
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